Login / Signup

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.

Hatem SolimanDeanna HogueHyo HanBlaise MooneyRicardo CostaMarie Catherine LeeBethany NiellAngela WilliamsAlec ChauShannon FalconNazanin KhakpourRobert J WeinfurtnerSusan HooverJohn KilukMarilin RosaHung KhongBrian Czerniecki
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The addition of TVEC to NAC was feasible at the approved dose, with manageable toxicity. The complete response rate was 55%.
Keyphrases
  • neoadjuvant chemotherapy
  • locally advanced
  • sentinel lymph node
  • lymph node
  • transcription factor
  • study protocol
  • oxidative stress
  • phase iii
  • early stage
  • phase ii
  • replacement therapy
  • open label